additional navigation


  • About AOP Orphan
    Slideshow Image

    About AOP Orphan

    Since its establishment 1996, AOP Orphan has focused on finding innovative solutions for Rare Diseases. Today AOP Orphan is a European pioneer in the field of Rare Diseases.

  • Patients & Relatives
    Slideshow Image

    Patients & Relatives

    Patients with rare disease often obtain little support. AOP Orphan saw potential in this need and is pleased to provide these patients with individualized therapies.

  • Medical Professionals
    Image for medical professionals

    Medical Professionals

    In the areas for medical professionals, you can find current information about products, treatment areas and study summaries for individual topics. You can either sign up using the AOP Orphan Account Service or log in using your DocCheck password.


A Pioneer in Rare Diseases

AOP Orphan was one of the first companies to enter the sector of rare diseases in Europe and to this day, continues to be a trailblazer in the field of Orphan Diseases. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. Today AOP Orphan is active at an international scale with an export ratio of about 70% and has become a leading company in its home branch.


The Austrian pharmaceutical pioneer AOP Orphan is now bringing Lojuxta® (lomitapide) Capsules to the Austrian market

Today AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, announced the creation of Rigi Orphan Inc, USA.  The new company will focus on...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®,...